Clinical trials: Hepatocellular Carcinoma Non-resectable
Hepatocellular Carcinoma
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
The purpose of this study is to compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy.
- Trial name
- BRISK TA (NCT00908752)
- Testing
- Brivanib, TACE Therapy
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 734 people
- Sponsor
- Bristol-Myers Squibb
Liver Cancer
Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00524316
- Testing
- doxorubicin hydrochloride, sunitinib malate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Hepatocellular Carcinoma
OREIOS International Study
Considering the treatment landscape with its dynamic algorithms and new approaches of sequencing, it is important to identify patient management patterns and survival outcomes arising from the current standard of care.
- Trial name
- OREIOS (NCT05239507)
- Where
- 21 sites in Brazil, Egypt and 9 more
- Volunteers
- 1,127 people
- Sponsor
- AstraZeneca
Liver Malignant Tumors, Cholangiocarcinoma Metastatic
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
Over the past three decades, the treatment of both primary and secondary liver malignancies has been improved by the development and optimization of multiple minimally invasive thermal ablative therapies.
- Conditions
- Liver Malignant Tumors, Cholangiocarcinoma Metastatic, Pancreatic Cancer, Melanoma
- Trial name
- NCT05053555
- Testing
- high dose rate brachytherapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Liver Cancer
Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis
RATIONALE: Sorafenib tosylate and pravastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT01075555
- Testing
- pravastatin sodium, sorafenib tosylate
- Where
- France
- Volunteers
- 323 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Hepatocellular Carcinoma Non-resectable
Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma
The study investigates the adjuvant SBRT following TACE in early and intermediate stages HCC not amenable for surgical resection.
- Trial name
- ASTrH (NCT04996914)
- Testing
- TACE, SBRT
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- RWTH Aachen University
Hepatocellular Carcinoma
Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC
Safety and Efficacy Study of Radioembolization with Yttrium-90 Microspheres in Combination with Durvalumab in Locally Advanced Hepatocellular Carcinoma
- Trial name
- SOLID (NCT04124991)
- Testing
- Durvalumab, Radioembolization
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Seoul National University Hospital
Liver Cancer, Hepatoma
Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an Option
Fewer than 15% of hepatoma patients are suitable candidates for surgical removal of their cancer. The purpose of this protocol is to provide supervised access at Oregon Health and Science University to Y-90 treatment to provide…
- Trial name
- Y-90HDE (NCT00740753)
- Testing
- Yttrium 90 (TheraSphere)
- Volunteers
- 339 people
- Sponsor
- OHSU Knight Cancer Institute
Liver Cancer
Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer
RATIONALE: Vaccines made from DNA and a gene-modified virus may make the body build an immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of…
- Trial name
- NCT00093548
- Testing
- alpha fetoprotein adenoviral vector vaccine, alpha fetoprotein plasmid DNA vaccine, sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant
- Sponsor
- Jonsson Comprehensive Cancer Center
Hepatocellular Carcinoma (HCC)
TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC
This study is a single-arm, multicenter, prospective clinical trial designed to evaluate the efficacy and safety of Transarterial Chemoembolization (TACE) combined with envafolimab in patients with unresectable, non-metastatic…
- Trial name
- TACE HCC (NCT06990620)
- Testing
- TACE+AK112
- Volunteers
- 56 people
- Sponsor
- Fudan University
Unresectable Hepatocellular Carcinoma
A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
This clinical trial was designed to evaluate the safety and efficacy of Y90-SIRT combined with nivolumab, ipilimumab, and lenvatinib in patients with unresectable HCC.
- Trial name
- NCT07482059
- Testing
- ttrium-90 microspheres in combination with nivolumab, ipilimumab, and lenvatinib in patients with unresectable hepatocellular carcinoma
- Where
- China
- Volunteers
- 33 people
- Sponsor
- West China Hospital
Liver Cancer
TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
RATIONALE: TAC-101 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of TAC-101 and to see how well it works in treating patients with…
- Trial name
- NCT00077142
- Testing
- TAC-101
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Unresectable Hepatocellular Carcinoma
Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors and the leading cause of cancer-related death worldwide. Surgical resection has always been the best hope for long-term survival of patients with HCC.
- Trial name
- NCT06896396
- Testing
- Lenvatinib, Pembrolizumab, Icaritin soft capsules, TACE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhiyong Huang
Carcinoma, Hepatocellular
A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma
This is a phase 2, open-label study to evaluate the safety, tolerability and efficacy of Irpagratinib in combination with Atezolizumab and Bevacizumab in patients with advanced or unresectable HCC harboring FGF19 overexpression.
- Trial name
- IAPETUS (NCT07010497)
- Testing
- irpagratinib
- Where
- 3 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- Asan Medical Center
HCC - Hepatocellular Carcinoma
Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC
The goal of this clinical trial is to learn whether adding branched-chain amino acids (BCAAs) to lenvatinib and pembrolizumab improves treatment outcomes in adults with unresectable hepatocellular carcinoma (HCC).
- Trial name
- BLP-HCC (NCT07412054)
- Testing
- Lenvatinib, Pembrolizumab, Branched-Chain Amino Acids
- Volunteers
- 234 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma Non-resectable
Pilot Clinical Trial to Evaluate the UNI-DEB for Unresectable Hepatocellular Carcinoma
Pilot Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma
- Trial name
- NCT03564405
- Testing
- UNI-DEB
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma Non-resectable
Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma
This prospective clinical trial will evaluate PET/CT and genomic liquid biopsy based biomarkers as predictors of clinical therapeutic response to immune-checkpoint inhibitor (ICI) therapy for patients with inoperable…
- Trial name
- ExTRACT-HCC (NCT04965454)
- Testing
- Fluorine-18 fluorocholine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Queen's Medical Center
Hepatocellular Carcinoma
A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC
This is a Phase II , Open-label , Investigator-initiated Trail of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With unresectable Hepatocellular Carcinoma.
- Trial name
- HZ-T-PD1-APA (NCT03793725)
- Testing
- SHR1210, Apatinib
- Volunteers
- 30 people
- Sponsor
- Yanqiao Zhang
Hepatocellular Carcinoma
TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma
The purpose of this study is to determine if TACE plus Recombinant Human Adenovirus Type 5 Injection will improve outcome in patients with advanced hepatocellular carcinoma (HCC) not amenable to surgery or local ablative therapy.
- Trial name
- NCT01869088
- Testing
- Recombinant Human Adenovirus Type 5 Injection, Transartery Chemoembolization
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Sun Yat-sen University
Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
The purpose of this study is to determine the effects that Regorafenib in combination with Yttrium-90 (Y-90) radioembolization has on patients with unresectable hepatocellular carcinoma.
- Trial name
- NCT06902246
- Testing
- Regorafenib, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization
- Sponsor
- University of Miami